AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · IEX Real-Time Price · USD
7.88
+0.16 (2.07%)
Jul 2, 2024, 4:00 PM EDT - Market closed
AVITA Medical Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for AVITA Medical stock have an average target of 24.25, with a low estimate of 9.00 and a high estimate of 40. The average target predicts an increase of 207.74% from the current stock price of 7.88.
Analyst Consensus: Buy
* Price targets were last updated on May 14, 2024.
Analyst Ratings
The average analyst rating for AVITA Medical stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $21 → $9 | Buy → Hold | Downgrades | $21 → $9 | +14.21% | May 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $22 → $21 | Buy | Maintains | $22 → $21 | +166.50% | May 14, 2024 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $19 → $21 | Buy | Reiterates | $19 → $21 | +166.50% | Feb 23, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $22 → $25 | Buy | Maintains | $22 → $25 | +217.26% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
77.17M
from 51.57M
Increased by 49.63%
Revenue Next Year
105.74M
from 77.17M
Increased by 37.03%
EPS This Year
-1.44
from -1.40
EPS Next Year
-0.75
from -1.44
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 82.8M | 120.8M | 155.5M | 142.3M |
| Avg | 77.2M | 105.7M | 135.2M | 138.2M |
| Low | 67.5M | 85.8M | 113.7M | 132.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 60.6% | 56.5% | 47.1% | 5.3% |
| Avg | 49.6% | 37.0% | 27.8% | 2.3% |
| Low | 30.9% | 11.2% | 7.5% | -1.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.32 | -0.14 | 0.35 | 0.21 |
| Avg | -1.44 | -0.75 | 0.11 | 0.20 |
| Low | -2.29 | -2.25 | -0.13 | 0.19 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | 91.6% |
| Avg | - | - | - | 86.2% |
| Low | - | - | - | 78.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.